Share/Bookmark

Published Research Studies and Abstracts Supported by Cure JM

Research Studies

Composition of Calcifications in Children with Juvenile Dermatomyositis with Chronic Cutaneous Inflammation.

Pachman LM , Veis A, Stock A, Abbott K, Vicari F, Byrd R, Giczewski D, Webb C, Spevak L, Boskey AL. Arthritis Rheum 54: 3345-3350, 2006. PMID: 17009308.
www.ncbi.nlm.nih.gov/pmc/articles/PMC2329813/

Immunogenetic risk and protective factors for juvenile dermatomyositis in Caucasians.

Mamyrova G, O’Hanlon TP, Monroe JB, Mercatante Carrick  D, Malley JD, Adams S, Reed AM,  Shamim EA, James-Newton L, Miller FW, Rider LG,  for the Childhood Myositis Heterogeneity Collaborative Study Group.  Arthritis and Rheumatism.  2006; 54: 3979 – 3987.
www.ncbi.nlm.nih.gov/pmc/articles/PMC2063456/

HLA Polymorphisms in African-Americans with idiopathic inflammatory myopathy: allelic profiles distinguish patients with different clinical phenotypes and myositis autoantibodies.

O'Hanlon TP, Rider LG, Mamyrova G, Targoff IN, Arnett FC, Reveille JD, Carrington M, Gao X, Oddis CV, Morel PA, Malley JD, Malley K, Shamim EA, Chanock SJ, Foster CB, Bunch T, Reed AM, Love LA, Miller FW. Arthritis and Rheum 2006; 54: 3670-3681.
www.ncbi.nlm.nih.gov/pubmed/17075818
/

Duration of illness is an important variable for untreated children with juvenile dermatomyositis.

Pachman LM, Abbott K, Sinacore JM, Amoruso L, Dyer A, Lipton RL, Ilowite N, Hom C, Cawkwell G, White A, Rivas-Chacon R, Kimura Y, Ray R, Ramsey-Goldman R. J.Pediatr. 148 (2):247-253, 2006. PMID: 16492437.

MxA gene expression in juvenile dermatomyositis peripheral blood mononuclear cells: Association with muscle involvement.

O'Connor KA, Abbott, KA, Sabin B, Kuroda M, Pachman LM. Clin Immun 120: 125-319-325, 2006. PMID: 16859997.

RANKL: Osteoprotegerin ratio and bone mineral density in children with untreated juvenile dermatomyositis.

Rouster-Stevens KA, Langman CB, Price HE, Seshadri R, Shore RM, Abbott K, Pachman LM. RANKL: Osteoprotegerin ratio and bone mineral density in children with untreated juvenile dermatomyositis. Arthritis Rheum. 56(3): 977-983, 2007. PMID: 17328075. (Cure JM supported Kelly Rouster-Stevens)
http://onlinelibrary.wiley.com/doi/10.1002/art.22433/pdf

Late-Onset Gastrointestinal Pain in Juvenile Dermatomyositis as a Manifestation of Ischemic Ulceration from Chronic Endarteropathy.

Mamyrova G, Kleiner DE, James-Newton L, Shaham B, Miller FW, Rider LG.  Arthritis and Rheumatism (Arthritis Care and Research). 2007; 57: 881 - 884.
www.ncbi.nlm.nih.gov/pmc/articles/PMC2099313/

Apoptosis in the skeletal muscle of untreated children with Juvenile Dermatomyositis: Impact of duration of untreated disease.

Zhao Y-D, Fedczyna TO, McVicker V, Caliendo J, Li H, Pachman LM. Clin Immunol. 125(2):165-172, 2007. PMID: 17704000.
www.ncbi.nlm.nih.gov/pmc/articles/PMC2219965/

Duration of chronic inflammation alters gene expression in muscle from untreated girls with juvenile dermatomyositis.

Chen Y-W, Shi R, Geraci N, Shrestha S, Gordish-Dressman H, Pachman LM. BMC Immunology, 9:43, 2008. PMID: 18671865.
www.ncbi.nlm.nih.gov/pmc/articles/PMC2529263/

Autoantibody to signal recognition particle in African American girls with juvenile polymyositis.

Rouster-Stevens KA, Pachman LM. J Rheumatol 35:927-929, 2008. PMID: 18322984. www.jrheum.org/content/35/5/927.long

Persistent Association of Nailfold Capillaroscopy Changes and Skin Involvement Over Thirty-Six Months With Duration of Untreated Disease in Patients With Juvenile Dermatomyositis.

Christen-Zaech S; Seshadri R, Sundberg J, Paller AS, Pachman LM. Persistent Association of Nailfold Capillaroscopy Changes and Skin Involvement Over Thirty-Six Months With Duration of Untreated Disease in Patients With Juvenile Dermatomyositis. Arthritis Rheum 58:571-576, 2008. PMID: 18240225.
www.ncbi.nlm.nih.gov/pmc/articles/PMC2830145/

Cytokine Gene Polymorphisms as Risk and Severity Factors for Juvenile Dermatomyositis.

Mamyrova G, O'Hanlon TP, Sillers L, Malley K, James-Newton L, Parks CG, Cooper GC, Pandey JP, Miller FW, Rider LG, for the Childhood Myositis Heterogeneity Collaborative Study Group. Arthritis and Rheumatism. 2008; 58: 3941-3950. www.ncbi.nlm.nih.gov/pubmed/19035492/

Pharmacokinetic study of oral prednisolone compared with intravenous methylprednisolone in patients with juvenile dermatomyositis.

Rouster-Stevens KA, Gursahaney A, Ngai K-L, Daru JA, Pachman LM. Arthritis Rheum (Arthritis Care Res) 59: 222-226, 2008. PMID: 18240180.
www.ncbi.nlm.nih.gov/pmc/articles/PMC2852143/

Predictors of Acquired Lipodystrophy in Juvenile-Onset Dermatomyositis and a Gradient of Severity.

Bingham A, Mamyrova G, Rother KI, Oral E, Cochran E, Premkumar A, Kleiner D, James-Newton L,   Targoff IN, Pandey JP, Mercatante Carrick D, Sebring N, O’Hanlon TP, Ruiz Hidalgo M, Turner M, Gordon LB,  Laborda J, Bauer SR, Blackshear PJ, Imundo L, Miller FW, Rider LG, for the Childhood Myositis Heterogeneity Study Group. Medicine.2008; 87: 70- 86.
www.ncbi.nlm.nih.gov/pmc/articles/PMC2674585/

Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood.

Feldman B, Rider L, Reed A, Pachman LM. Lancet. 2008 Jun 28;371(9631):2201-12. PMID: 18586175. www.thelancet.com/journals/lancet/article/PIIS0140-6736(08)60955-1/fulltext

The role of aggressive corticosteroid therapy in patients with juvenile dermatomyositis: a propensity score analysis.

Seshadri R, Feldman B, Ilowite N, Cawkwell GD, Pachman LM. Arthritis Care Res 59:989-995, 2008. PMID: 18576304

On Determining the Effects of Therapy on Disease Damage in Non-randomized Studies with Multiple Treatments: A study of Juvenile Myositis. 

Lachenbruch PA, Miller FW, Rider LG. Comm. In Statist. - Theory and Methods.  2009, 38: 3268-3281. 
www.ncbi.nlm.nih.gov/pmc/articles/PMC2832328/

Juvenile dermatomyositis calcifications selectively displayed markers of bone formation.

Urganus AL, Zhao Y-D, Pachman LM. Arthritis Rheum. 2009 Apr 15;61(4):501-8. PMID: 19333978. www.ncbi.nlm.nih.gov/pmc/articles/PMC2741135/

Elevated serum interferon-alpha activity in juvenile dermatomyositis: associations with disease activity at diagnosis and after thirty-six months of therapy.

Niewold TB, Kariuki SN, Morgan GA, Shrestha S, Pachman LM. Arthritis Rheum. 2009 Jun;60(6):1815-24. PMID: 19479879.
www.ncbi.nlm.nih.gov/pmc/articles/PMC2697261/

Characterization of dystrophic calcification induced in mice by cardiotoxin.

Zhao Y-D, Urganus A, Spevak L, Shrestha S, Doty SB, Boskey AL, Pachman LM. Calcif Tissue Int. 2009 Sep;85(3):267-75. Epub 2009 Aug 20. PMID: 19690791.
www.ncbi.nlm.nih.gov/pmc/articles/PMC2830143/

Damage Extent and Predictors in Adult and Juvenile Dermatomyositis and Polymyositis Using the Myositis Damage Index.

Rider LG, Lachenbruch PA, Monroe JB, Ravelli A, Cabalar I, Feldman BM, Villalba ML, Myones BL,  Pachman LM, Rennebohm RM, Reed AM, Miller FW, for the International Myositis Assessment and Clinical Studies Group (IMACS).  Arthritis and Rheumatism, 2009;60(11):3425-3435.
www.ncbi.nlm.nih.gov/pmc/articles/PMC2793533/

Protocols for the initial treatment of moderately severe juvenile dermatomyositis: results of a children's arthritis and rheumatology research alliance consensus conference.

Huber AM, Giannini EH, Bowyer SL, Kim S, Lang B, Lindsley CB, Pachman LM, Pilkington C, Reed AM, Rennebohm RM, Rider LG, Wallace CA, Feldman BM. Arthritis Care Res (Hoboken). 2010 Feb;62(2):219-25. PMID: 20191521. www.ncbi.nlm.nih.gov/pmc/articles/PMC2909837/

Calcification in a case of circumscribed myositis ossificans.

Ibarra M, Chou PM, Pachman LM, Zhao YD, Boskey AL. J Rheumatol. 2010 Apr;37(4):876. PMID: 20360204. www.ncbi.nlm.nih.gov/pmc/articles/PMC3357497/

Association of normal nailfold end row loop numbers with a shorter duration of untreated disease in children with juvenile dermatomyositis.

Ostrowski R, Sullivan C, Seshadri R, Morgan GA, Pachman LM. Arthritis Rheum. 2010 May;62(5):1533-8. PMID: 20213809.
www.ncbi.nlm.nih.gov/pmc/articles/PMC3304541/

Lesional and nonlesional skin from patients with untreated juvenile dermatomyositis displays increased numbers of mast cells and mature plasmacytoid dendritic cells.

Shrestha S, Wershil B, Sarwark JF, Philipp T, Pachman LM. Arthritis Rheum. 2010 Sept;62(9):2813–22. PMID: 20506305.
www.ncbi.nlm.nih.gov/pmc/articles/PMC3312790/

Mycophenolate mofetil: a possible therapeutic agent for children with juvenile dermatomyositis.

Rouster-Stevens K, Morgan G, Wang D, Pachman LM. Arthritis Care Res (Hoboken). 2010;62(10): 1446-51. PMID: 20521307.
www.ncbi.nlm.nih.gov/pmc/articles/PMC2952049/

Gene-gene-sex interaction in cytokine gene polymorphisms revealed by serum interferon alpha phenotype in juvenile dermatomyositis.

Niewold TB, Kariuki SN, Morgan, GA, Shrestha S, Pachman LM. J Pediatr. 2010 Oct;157(4):653-57 PMID: 20605164.
www.ncbi.nlm.nih.gov/pmc/articles/PMC2936662/

Environmental Factors Preceding Illness Onset in the Juvenile Idiopathic Inflammatory Myopathies.

Rider LG, Wu L, Mamyrova G, Targoff IN, Miller FW, for the Childhood Myositis Heterogeneity Collaborative Study Group. Rheumatology. 2010; 49(12):2381-90.
www.ncbi.nlm.nih.gov/pmc/articles/PMC2981509/

Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies.

Rider L, Koziol D, Giannini E, Jain M, Smith M, Whitney-Mahoney K, Feldman M, Wright S, Lindsley C, Pachman LM, Villalba M, Lovell D, Bowyer S, Plotz P, Miller F, Hicks J. Arthritis Rheum. 2010 Apr;62(4):465-72. PMID: 20391500

The Paediatric Rheumatology International Trials Organization provisional criteria for the evaluation of response to therapy in juvenile dermatomyositis.

Ruperto N, Pistorio A, Ravelli A, Rider L, Pilkington C, Oliveira S, Wulffraat N, Espada G, Garay S, Cuttica R, Hofer M, Quartier P, Melo-Gomes J, Reed A, Wierzbowska M, Feldman B, Harjacek M, Huppertz H, Nielsen S, Flato B, Lahdenne P, Michels H, Murray KJ, Punaro L, Rennebohm R, Russo R, Balogh Z, Rooney M, Pachman LM, Wallace C, Hashkes P, Lovell DJ, Giannini EH, Gare B, Martini A; Paediatric Rheumatology International Trials Organisation (PRINTO); Pediatric Rheumatology Collaborative Study Group (PRCSG). Arthritis Care Res (Hoboken). 2010 Nov;62(11):1533-41. PMID: 20583105

Environmental factors preceding illness onset differ in phenotypes of the juvenile idiopathic inflammatory myopathies.

Rider L, Wu L, Mamyrova G, Targoff IN, Miller FW; Childhood Myositis Heterogeneity Collaborative Study Group. Rheumatology (Oxford). 2010 Dec;49(12):2381–2390; Epub 2010 Aug 27. PMID: 20802007

Autoantibody to PL-12 (Anti-Alanyl-tRNA synthetase) in an African American girl with juvenile dermatomyositis and resolution of interstitial lung disease.

Vega P, Ibarra M, Prestridge A, Pachman LM. J Rheumatol. 2011 Feb;38(2):394-5. PMID: 21285181. www.jrheum.org/content/38/2/394.long

Serum neopterin levels as a diagnostic marker of hemophagocytic lymphohistiocytosis syndrome.

Ibarra M, Klein-Gitelman M, Morgan E, Proytcheva M, Sullivan C, Morgan G, Pachman LM, O'Gorman MR. Clin Vaccine Immunol. 2011 Apr;18(4):609-14. Epub 2011 Jan 26. PMID: 21270283.
www.ncbi.nlm.nih.gov/pmc/articles/PMC3122569/

Familial aggregation of autoimmune disease in juvenile dermatomyositis.

Niewold T, Wu S, Smith M, Morgan GA, Pachman LM. Pediatrics. 2011 May;127(5):e1239-46. Epub 2011 Apr 18. PMID: 21502224.
www.ncbi.nlm.nih.gov/pmc/articles/PMC3081190/

Double trouble: therapeutic challenges in patients with both juvenile dermatomyositis and psoriasis.

Kim NN, Lio PA, Morgan GA, Jarvis J, Pachman LM. Arch Dermatol. 2011 Jul;147(7):831-5. Epub 2011 Mar 21. PMID: 21422326.
http://archderm.jamanetwork.com/article.aspx?articleid=1105129

Clinical status and cardiovascular risk profile of adults with a history of juvenile dermatomyositis.

Eimer M, Brickman W, Seshadri R, Ramsey-Goldman R, McPherson D, Smulevitz B, Stone N, Pachman LM. J Pediatr. 2011 Nov;159(5):795-801. Epub 2011 Jul 23. Jul 22. PMID: 21784434.
www.ncbi.nlm.nih.gov/pmc/articles/PMC3193560/

Ovarian teratoma mimicking features of juvenile dermatomyositis in a child.

Ibarra M, Chou P, Pachman LM. Pediatrics. 2011 Nov;128(5):e1293-6. Epub 2011 Oct 3. PMID: 21969283. www.ncbi.nlm.nih.gov/pmc/articles/PMC3208967/

Parents’ perception of self-advocacy of children with myositis: an anonymous online survey. 

Katz JD, Mamyrova G, Agarwal S, Jones OY, Bollar H, Huber AM, Rider LG, White PH.  Pediatric Rheumatology. 2011, 9:10.
www.ncbi.nlm.nih.gov/pmc/articles/PMC3118375/

Ovarian teratoma mimicking features of juvenile dermatomyositis in a child.

Ibarra M, Chou P, Pachman LM. Pediatrics. 2011 Nov;128(5):e1293-6. Epub 2011 Oct 3. PMID: 21969283

Methylation alterations of WT1 and homeobox genes in inflamed muscle biopsies from untreated juvenile dermatomyositis suggests self-renewal capacity.

Wang M, Xie H, Shrestha S, Sredni S, Morgan GA, Pachman LM. Arthritis Rheum. 2012 Oct;64(10):3478-85. PMID: 22674142.
www.ncbi.nlm.nih.gov/pmc/articles/PMC3462248/

Increased expression of vascular cell adhesion molecule 1 in muscle biopsy samples from juvenile dermatomyositis patients with short duration of untreated disease is regulated by miR-126.

Kim E, Cook-Mills J, Morgan GA, Sredni ST, Pachman LM. Kim E, Cook-Mills J, Morgan GA, Sredni ST, Pachman LM. Arthritis Rheum. 2012 Nov;64(11):3809-17. PMID: 22740338.
www.ncbi.nlm.nih.gov/pmc/articles/PMC3469762/

The Myositis Autoantibody Phenotypes of the Juvenile Idiopathic Inflammatory Myopathies.

Shah M, Mamyrova G, Targoff IN,
Huber AM, Malley JD, Rice MM, Miller FW, Rider LG, with the Childhood Myositis Heterogeneity Collaborative Study Group*Þ Medicine 2013; 92:(4):223-243. www.ncbi.nlm.nih.gov/pmc/articles/PMC3721421/

Clinical and laboratory features distinguishing juvenile polymyositis and dystrophies.

Mamyrova G, Katz JD, Jones RV, Targoff IN, Lachenbruch PA, Jones OY, Miller FW, Rider LG for the Childhood Myositis Heterogeneity Study Group. Arthritis Care Res (Hoboken) 2013; 65 (12): 1969-75.doi 10.1002/acr.22088.
www.ncbi.nlm.nih.gov/pubmed/23925923/

Early Illness Features Associated with Mortality in the Juvenile Idiopathic Inflammatory Myopathies.

Huber AM, Mamyrova G, Lachenbruch PA, Lee JA, Katz JD, Targoff IN, Miller FW, and Rider LG, for the Childhood Myositis Heterogeneity Study Group. Arthritis Care Res (Hoboken). 2014 May;66(5):732-40. www.ncbi.nlm.nih.gov/pubmed/24151254/

Cytokine Gene Polymorphisms as Risk and Severity Factors for Juvenile Dermatomyositis. 

Mamyrova G., O’Hanlon TP, Sillers L, Malley K, James-Newton L, Parks CG, Cooper GS, Pandey  JP, Miller FW, Rider LG, for the Childhood Myositis Heterogeneity Collaborative Study Group. Arthritis and Rheumatism.  2008; 58: 3941 - 3950.
www.ncbi.nlm.nih.gov/pmc/articles/PMC2674642/

The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies.

Rider LG, Shah M, Mamyrova G,* Huber AM,* Rice MM, Targoff IN, Miller FW, for the Childhood Myositis Heterogeneity Collaborative Study Group. Medicine (Baltimore). 2013. 92: 223-243.
www.ncbi.nlm.nih.gov/pubmed/23877355
/

Brief report: ultraviolet radiation exposure is associated with clinical and autoantibody phenotypes in juvenile myositis. 

Shah M, Targoff IN, Rice MM, Miller FW, Rider LG; Childhood Myositis Heterogeneity Collaborative Study Group. Arthritis Rheum. 2013 Jul;65(7):1934-41.
www.ncbi.nlm.nih.gov/pubmed/23658122/

Detection of anti-Ro, La, Smith and RNP autoantibodies by autoantigen microarray analysis and interferon-alpha induction in juvenile dermatomyositis.

Balboni I, Niewold TB, Morgan GA, Limb C, Eloranta M-L, Rönnblom L, Utz PJ, Pachman LM. Arthritis & Rheumatism 2013 Sept, 65 (9) 2424-2429. PMID: 23740815

Pulmonary Function Tests in Idiopathic Inflammatory Myopathy: Association with Clinical Parameters.

Prestridge A, Morgan MA, Ferguson L, Huang S, Pachman LM. Arthritis Care and Research,2013 65,Sept (9) 1424-1431. PMID 23568855

Four year olds, healthy or recovering from Juvenile Dermatomyositis do not achieve a full Childhood Myositis Assessment Scale (CMAS).

Quinones R, Morgan GA, Amoruso M, Field R, Pachman LM. Arthritis Care and Research. October 2013;65(10):1697-1701. PMID 23666925

The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies.

Rider LG, Shah M, Mamyrova G, Huber AM, Rice MM, Targoff IN, Miller FW; Childhood Myositis Heterogeneity Collaborative Study Group. Medicine (Baltimore). 2013 Jul;92(4):223-43. PMID: 238773

Brief report: ultraviolet radiation exposure is associated with clinical and autoantibody phenotypes in juvenile myositis.

Shah M, Targoff IN, Rice MM, Miller FW, Rider LG; Childhood Myositis Heterogeneity Collaborative Study Group. Arthritis Rheum. 2013 Jul;65(7):1934-41. PMID: 23658122

The clinical phenotypes of the juvenile idiopathic inflammatory myopathies.

Shah M, Mamyrova G, Targoff IN, Huber AM, Malley JD, Rice MM, Miller FW, Rider LG; Childhood Myositis Heterogeneity Collaborative Study Group. Medicine (Baltimore). 2013 Jan;92(1):25-41. PMID: 23263716

Genome-wide Association Study of Dermatomyositis Reveals Genetic Overlap with other Autoimmune Disorders.

Miller FW, Cooper RG, Ivencovsky J, Rider LG, Danko, K Wedderburn LR, Lundberg IE, Pachman LM, Reed AM, Ytterberg SR, Padyukov L, Selva-O'Callaghan A, Radstake T, Isenberg DA, Chinoy H, Ollier WER, O'Hanlon TP, Peng B, Lee A, Lamb JA, Chen W, Amos CI, Gregersen PK with the Myositis Genetics Consortium. Arthritis & Rheumatism. 2013 December(12);65:3239-3247. PMID: 23983088

Clinical and laboratory features distinguishing juvenile polymyositis and muscular dystrophy.

Mamyrova G, Katz JD, Jones RV, Targoff IN, Lachenbruch PA, Jones OY, Miller FW, Rider LG; Childhood Myositis Heterogeneity Collaborative Study Group. Arthritis Care Res (Hoboken). 2013 Dec;65(12):1969-75. PMID: 23925923

Pilot Study of Etanercept in Patients with Refractory Juvenile Dermatomyositis

Rouster-Stevens K, Ferguson L, Morgan G, Huang C-C, Pachman LM. 2014 May;66(5):783-787. PMID 24127327

Early illness features associated with mortality in the juvenile idiopathic inflammatory myopathies.

Huber AM, Mamyrova G, Lachenbruch PA, Lee JA, Katz JD, Targoff IN, Miller FW, Rider LG; Childhood Myositis Heterogeneity Collaborative Study Group. Arthritis Care Res (Hoboken). 2014 May;66(5):732-40. PMID 24151254

Anti-p155/140 autoantibodies and early clinical features are associated with disease course in the juvenile idiopathic inflammatory myopathies.

Habers GE, Huber AM, Mamyrova G, Targoff IN, Boonacker C, van Brussel M, Miller FW, van Royen-Kerkhof A, Rider LG, Childhood Myositis Heterogeneity Study Group. Annals of the Rheumatic Diseases, submitted for review.

miRNA-10a Regulation of Proinflammatory Mediators: An Important Component in Untreated Juvenile Dermatomyositis (JDM).

Xu D, Huang CC, Kachaochana A, Morgan GA, Bonaldo MF, Soares MB, Sarwark J, SSredni Pachman LM. J Rheum 2015. (In press)

Dense Genotyping of Immune-Related Loci in the Idiopathic Inflammatory Myopathies Confirms HLA alleles as Strongest Genetic Risk Factor and Suggests Different Genetic Background for Major Clinical Subgroups.

Rothwell, S et al. Annals of the Rheumatic Diseases 2015 (In press)

Monitoring Change in Volume of Calcifications in Juvenile Myositis: A Pilot Study using Low Dose Computed Tomography (CT).

Ibarra M, Rigsby C, Morgan GA, Sammet CL, Huang CC, Xu D, Targoff IN, Pachman LM. (Under review)

Abstracts

  1. G. Mamyrova, L. Sillers, T. O'Hanlon, J. Pandey, C. Parks, J. Malley, L. James-Newton, C. Wallace, D. Sherry, L. Imundo, C. Lindsley, K. Madson, M. Perez, G. S. Cooper, F. Miller, L. Rider, and the Childhood Myositis Heterogeneity Study Group. Interleukin-1 and Tumor Necrosis Factor Alpha Polymorphisms are Risk and Protective Factors for Juvenile Dermatomyositis (JDM). Arthritis and Rheumatism.  2006; 54 (suppl): S831. 
  2. G. Mamyrova, L. Sillers, T. O'Hanlon, J. Pandey, J. Malley, S. Adams, L. James-Newton, C. Wallace, D. Sherry, L. Imundo, C. Lindsley, K. Madson, M. Perez, F. Miller, L. Rider, and the Childhood Myositis Heterogeneity Study Group. Cytokine and HLA Alleles Modulate Disease Severity in Juvenile Dermatomyositis (JDM).   Arthritis and Rheumatism.  2006; 54 (suppl): S692-693. 
  3. A Bingham, G Mamyrova, E Cochran, E Oral, L James-Newton, A Pokrovnichka, L Imundo, F Miller, L Rider, A Premkumar. MRI Characterization of Regional Fat Loss in Patients with Lipodystrophy Complicating Dermatomyositis.  Arthritis and Rheumatism.  2006; 54 (suppl): S169-170.
  4. Pachman LM, Abbott K, Zhao Y, Veis A, Boskey A. Characterization of pathologic calcification in active juvenile dermatomyositis (JDM). J Immunol 176:S214, abstract # 107.8, 2006.
  5. Zhao Y-D, Fedczyna TO, Kuroda M, McVicker V, Caliendo J, Abbott K, Li H, Pachman LM. Apopotsis Indices in the skeletal muscle of juvenile dermatomyositis: impact of duration of untreated disease. Arthritis Rheum 54:S657, 2006.
  6. Rouster-Stevens KA, Seshadri R, Shore RM, Abbott K, Pachman LM. RANKL/OPG is inversely associated with bone mineral density in juvenile dermatomyositis. Arthritis Rheum 54:S681, #1701, 2006.
  7. Pascual V, Patel P, McVicker V, Abbott K, Gurhsahaney A, Pachman LM. Peripheral blood mononuclear cell gene expression profiles in children with juvenile dermatomyositis/polymyositis (JDM/JPM) share type-1 interferon (IFN) signatures with Systemic Lupus Erythermatosus (SLE) but are distinct.  Arthritis Rheum 54:S695, # 1743, 2006.

  8. Rouster-Stevens KA, Pachman LM. Mycophenolate mofetil in Juvenile Dermatomyositis. Arthritis Rheum 54:S680, # 1700, 2006.

  9. Eimer MJ, Young L, Abbott K, Seshadri R, Gursahaney A , Smulevitz B, Rhew E, Ramsey-Goldman R,  McPherson D, Pachman LM.  Abnormal cardiovascular risk profile in adult patients with Juvenile Dermatomyositis. Arthritis Rheum 54:S 519, # 1243,2006.

  10. Pascual V, Patel P, McVicker V, Abbott K, Gurhsahaney A, Pachman LM. Peripheral blood mononuclear cell gene expression profiles in children with juvenile dermatomyositis/polymyositis (JDM/JPM) share type-1 interferon (IFN) signatures with Systemic Lupus Erythermatosus (SLE) but are distinct. Arthritis Rheum 54:S695, # 1743, 2006.

  11. Rouster-Stevens KA, Pachman LM. Mycophenolate mofetil in Juvenile Dermatomyositis. Arthritis Rheum 54:S680, # 1700, 2006.

  12. Eimer MJ, Young L, Abbott K, Seshadri R, Gursahaney A , Smulevitz B, Rhew E, Ramsey-Goldman R, McPherson D, Pachman LM. Abnormal cardiovascular risk profile in adult patients with Juvenile Dermatomyositis. Arthritis Rheum 54:S 519, # 1243,2006.

  13. G. Mamyrova, CA. Bingham, EA Oral, K. Rother, E. Cochran, N. Sebring, J. Pandey, L. James-Newton, T. O'Hanlon, I. Targoff, F. Miller, L. Rider. Clinical and Metabolic Characteristics of Acquired Lipodystrophy in Juvenile Dermatomyositis Arthritis and Rheumatism  2007; 55 (suppl): S145.
  14. Zhao YD, Urganus A, Chen Y-W, Stern PH , Boskey AL, Pachman LM. Role of cell death and osteogenic activity in injury-induced calcification in TNF-alpha receptor p55-/- p75-/- Mice. JBMR 22, S385, 2007.
  15. Zhao YD, Spevak L, Urganus A, Tse W, Boskey AL, Pachman LM. Comparison of transgenic mice as an animal model for calcinosis in Juvenile Dermatomyositis (JDM) Arthritis Rheum 56: S 654, 2007.
  16. Balboni I, Patel P, Limb C, Luera N, Morgan G, Utz P, Pascual V, Pachman LM. Autoantigen microarray analysis of sera from Juvenile Dermatomyositis patients: Association with an SLE-like type I interferon signature. Arthritis Rheum 56:S787, 2007.    
  17. L. Rider, P. Lachenbruch, L. James-Newton, I. Cabalar, B.M. Feldman, A. Ravelli, B. Myones, R. Rennebohm, L. Pachman, M. Villalba, E. Adams, C. Lindsley, C. Wallace, S. Ballinger, L. Zemel, A. Reed, F. Miller, IMACS Group Effects of Treatment on Disease Damage in Juvenile and Adult Myositis .  Arthritris and Rheumatism,  2008; 58S, S229.
  18. Ibarra M, Zhao Y-D, Boskey AL, Chou PM, Pachman LM. Characterization of calcification in circumscribed myositis ossificans by Fourier Transform Infrared Spectroscopic Imaging (FTIRI). Keystone meeting, Ped Rheumatology, 2008.
  19. Pachman LM, Shrestra S, Geraci N, Morgan GA, Chen Y-W. Duration of untreated Juvenile Dermatomyositis (JDM) at diagnosis: Impact on muscle biopsy (MBx) gene expression profiles, comparisons with polymyositis (PM). NIH muscle physiology meeting, New Orleans, 2008.
  20. Pachman LM, Geraci N, Morgan GA, Daniels B, Seshadri R, Sullivan D, O'Gorman MRG. Absolute number of circulating CD3-CD56+/CD16+ natural killer (NK) cells, a potential biomarker of disease activity in Juvenile Dermatomyositis (JDM). Arthritis Rheum 58(9):S225, 2008.
  21. Niewold TB, Kariuki SN, Morgan GA, Geraci N, Shrestha S, Pachman LM. Serum interferon alpha activity is associated with biological markers of disease activity and severity in Juvenile Dermatomyositis. Arthritis Rheum 58(9):S501, 2008.
  22. Scalici J, Zhao YD, Morgan GA, Sullivan C, Seshadri R, Pachman LM. Descriptive analysis of the clinical features of patients with Juvenile Dermatomyositis and Partial Lipodystrophy. Arthritis Rheum 58(9):S231, 2008.
  23. Ostrowski RA, Sullivan CL, Seshadri R, Morgan GA, Pachman LM. Normal nailfold end row loops are associated with a shorter duration of untreated disease in children with Juvenile Dermatomyositis. Arthritis Rheum 58(9):S255, 2008.
  24. Pachman LM, Neiwold TB, Kariuki SN, Morgan GA, Geraci N, Chen Y-W. Decreased type-1 Interferon in sera of untreated children with Juvenile Polymyositis (JPM) compared with Juvenile Dermatomyositis (JDM) matched for short disease duration. Arthritis Rheum 58(9):S225, 2008.
  25. Urganus AL, Zhao Y, Pachman LM. Calcifications in Children with Juvenile Dermatomyositis (JDM) contain several bone formation markers. JBMR 154, 23S1, 2008.
  26. Niewold T, Kariuki S, Morgan GA, Shrestha S, Pachman LM. Elevated serum interferon alpha activity in Juvenile Dermatomyositis: Associates with disease activity at diagnosis and after 36 months of therapy. Clin Immunol 131, supplement, S109, 2009.
  27. Balboni I, Niewold T, Morgan GA, Limb C, Eloranta ML, Utz P, Rönnbolm L, Pachman LM. Concordance of serologic data in Juvenile Dermatomyositis: Interferon-alpha induction and activity, and detectable levels of anti-ro and anti-la autoantibodies. Clin Immunol 131, supplement, S134, 2009.
  28. Pachman LM, Niewold T, Shrestha S, Morgan GA, Sullivan C. TNF-α Levels and IFN-α activity in children with Juvenile Dermatomyositis (JDM) are associated and modified by etanercept. Clin Immunol 131, supplement, S158, 2009.
  29. Shrestha S, Wershil B, Sarwark JF, Pachman LM. Increased mast cells in untreated JDM skin compared to paired JDM muscle: Association with mature plasmacytoid dendritic cells. Arthritis Rheum 60(10):S305, 2009.
  30. Geraci N, Pachman LM, Morgan GA, Chen Y-W. Juvenile Dermatomyositis (JDM): Responders and non-responders to medical therapy have differential genetic profiles. Arthritis Rheum 60(10):S496, 2009.2
  31. Niewold T, Wu S, Smith M, Morgan GA, Pachman LM. Familial aggregation of autoimmune disease in families of children with Juvenile Dermatomyositis: Family history of Lupus is associated with increased INF-α. Arthritis Rheum 60(10):S496, 2009.
  32. Ibarra MF, Klein-Gitelman M, Morgan E, Proytcheva M, Sullivan C, Morgan GA, Pachman LM, O'Gorman MRG. Evaluation of serum neopterin level as a diagnostic marker of Hemaphagocytic Lymphohistiocytosis syndrome (HLH). Arthritis Rheum 60(10):S496, 2009.
  33. Niewold TB, Kariuki SN, Morgan GA, Shrestha S, Pachman LM. Genetic regulation of serum IFN-α in Juvenile Dermatomyositis. Arthritis Rheum 60(10):S497, 2009.
  34. L. Rider, L. Wu, Gulnara. Mamyrova, D. Sherry, M. Perez, C. Wallace, L. Imundo, CA Bingham, L. Zemel, C. Lindsley, R. Rivas-Chacon, P. White, R. Rennebohm, M. Henrickson, I. Targoff, F. Miller and Childhood Myositis Heterogeneity Study Group.  Environmental Factors Preceding Illness Onset Differ in Phenotypes of the Juvenile Idiopathic Inflammatory Myopathies.  Arthritis and Rheumatism, 2010.  62S: S699-700.
  35. Ibarra M, Klein-Gitelman M, Morgan E, Proytcheva M, Sullivan C, Morgan GA, Pachman LM, O'Gorman MRG. Serum neopterin levels as a diagnostic marker of Hemophagocytic Lymphohistiocytosis Syndrome. Clin Immunol 135, supplement, T39, 2010.
  36. Niewold TB, Wu S, Smith M, Morgan GA, Pachman LM. Familial aggregation of autoimmune disease in families of children with Juvenile Dermatomyositis: Family history of Lupus is associated with increased IFN-α. Clin Immunol 135, supplement, S23, 2010.
  37. Ibarra M, Rigsby C, Morgan GA, Wang D, Pachman LM. Measuring Changes in calcifications in Juvenile Dermatomyositis (JDM) using single slice Computerized Tomography (CT). Arthritis Rheum 62(10):S702, 2010.
  38. Pachman LM, Wang M, Xie H, Hendrickson P, Shrestha S, Morgan GA. Epigenetic studies characteristic of muscle biopsies (MBx) from untreated children with Juvenile Myositis (JM). Arthritis Rheum 62(10):S345, 2010.
  39. Pachman LM, Chen Y-W, Hendrickson P, Shrestha S, Morgan GA, Sredni S. Pilot study of gene expression profile differences in Juvenile Dermatomyositis (JDM) responders and non-responders: Diagnostic and follow-up muscle biopsy data. Arthritis Rheum 62(10):S102, 2010.
  40. Sredni S, Hendrickson P, Shrestha S, Pachman LM. MicroRNA expression in Juvenile Dermatomyositis (JDM): clues to disease pathogenesis and chronicity. Arthritis Rheum 62(10):S384, 2010.
  41. FW Miller, RG Cooper, J Vencovsky, LG Rider, K Danko, LR Wedderburn, IE Lundberg, LM Pachman, AM Reed, SR Ytterberg, L Padyukov, A Selva O’Callaghan, TR Radstake, DA Isenberg, H Chinoy, W Ollier, TP O’Hanlon, B Peng, P Scheet, A Lee, JA Lamb, WV Chen, CI Amos, and PK Gregersen, with the Myositis Genetics Consortium.  Genome-wide Association Study of Dermatomyositis Reveals Shared Genetic Risk Factors with Other Autoimmune Diseases.  Arthritis and Rheumatism, 2011,63: S656.
  42. Sredni S, Hendrickson P, Morgan GA, Shrestha S, Huang CC, Chen YW, Pachman LM. Pathophysiology of untreated Juvenile Dermatomyositis muscle: Hypoxia and apoptosis are regulated by microRNAs. Clinical Immunology Society Annual Meeting, Chicago, 2011.
  43. Kim E, Cook-Mills J, Caliendo J, Morgan GA, Pachman LM. Short duration of untreated disease is associated with increased VCAM-1 expression in Juvenile Dermatomyositis diagnostic muscle biopsies. Clinical Immunology Society Annual Meeting, Chicago, May 2011.
  44. Kim E, Cook-Mills J, Morgan GA, Caliendo J, Sredni ST, Pachman LM. miRNA-126 regulates increased VCAM-1 expression in muscle biopsies from children with untreated Juvenile Dermatomyositis of short disease duration. Arthritis Rheum 2011;63 Suppl 10:32.
  45. Prestridge A, Morgan GA, Wang D, Pachman LM. Pulmonary function tests in idiopathic inflammatory myopathy: association with clinical parameters. Arthritis Rheum 2011;63 Suppl 10:248
  46. Wang M, Xie H, Hendrickson P, Shrestha S, Sredni ST, Morgan GA, Pachman LM. Epigenetic control of muscle repair identified in diagnostic muscle biopsies from untreated children with Juvenile Dermatomyositis. Arthritis Rheum 2011;63 Suppl 10:252.
  47. Sredni ST, Hendrickson P, Kim E, Morgan GA, Shrestha S, Chen Y, Huang C, Pachman LM. microRNAs miR-15b and miR-206 are key factors in the regulation of impaired angiogenesis in muscle of children with untreated Juvenile Dermatomyositis. Arthritis Rheum 2011;63 Suppl 10:819.
  48. Shrestha S, O'Gorman M, Orange J, Tessler-Verville C, Snow K, Morgan GA, Wang D, Pachman LM. Natural killer cells in untreated Juvenile Dermatomyositis: Altered peripheral blood receptors and increased localization in inflamed muscle. Arthritis Rheum 2011;63 Suppl 10:992.
  49. Miller F, Cooper R, Vencovsky J, Rider LG, Danko K, Wedderburn L, Lundberg I, Pachman LM, et al. Genome-wide association study of Dermatomyositis reveals shared genetic risk factors with other autoimmune diseases. Arthritis Rheum 2011;63 Suppl 10:1678.
  50. Quinones R, Morgan GA, Amoruso M, Wang D, Pachman LM. The Childhood Myositis Assessment Scale (CMAS) total score in healthy children, age 4-5 years, is 46, not 52. Arthritis Rheum 2011;63 Suppl 10:2011.
  51. AM Huber, G Mamyrova, J Lee, PA. Lachenbruch, IN. Targoff, FW. Miller and LG. Rider for the Childhood Myositis Heterogeneity Study Group.  Illness Features Associated with an Increased Risk of Mortality in Children with Juvenile Idiopathic Inflammatory Myopathies.  Arthritis and Rheumatism, 2012. 64 (suppl). S127-128.
  52. Pachman LM, Lintner KE, Wu YL, Ferguson LJ, Morgan GA, Huang CC, Yu CY. Decreased C4A Gene Copy Numbers in Children with Juvenile Dermatomyositis: Association with Decreased C4 Protein and Lower Absolute Number of CD3 Negative CD16/56+ Natural Killer Cells. Arthritis Rheum 2012; 64 Suppl 10:1948.;
  53. Pachman LM, Morgan GA, Curran ML, Ferguson LJ, Huang CC. Decreased Frequency of Dystrophic Calcifications in Children with Juvenile Dermatomyositis: A 10-Year Study. Arthritis Rheum 2012;64 Suppl 10:301.
  54. Xu D, Kachaochana A, Morgan GA, Vanin EF, Soares MB, Pachman LM. Microarray Analysis for microRNA Expression in Juvenile Dermatomyositis (JDM). Arthritis Rheum 2012;64 Suppl 10:1670.
  55. G. Mamyrova, JD. Katz, RV. Jones, P. Lachenbruch, M. Shah, OY. Jones, A Chahal, S Agrawal, FW. Miller, LG. Rider. Clinical and Laboratory Features Distinguishing Juvenile Polymyositis and Muscular Dystrophy in Children.  Arthritis and Rheumatism, 2012. 64 (suppl). S123.
  56. Xu D, Kachaochana A, Morgan GA, Vanin EF, Soares MB, Pachman LM. Microarray analysis for microRNA Expression in Juvenile Dermatomyositis (JDM). Arthritis Rheum 2012;64 Suppl 10:1670.
  57. Pachman LM, Lintner KE, Wu YL, Ferguson LJ, Morgan GA, Huang CC, Yu CY. Decreased C4A gene copy numbers in children with Juvenile Dermatomyositis: Association with decreased C4 protein and lower absolute number of CD3 negative CD16/56+ natural killer cells. Arthritis Rheum 2012;64 Suppl 10:1948.
  58. Pachman LM, Morgan GA, Curran ML, Ferguson LJ, Huang CC. Decreased frequency of dystrophic calcifications in children with Juvenile Dermatomyositis: A 10-Year Study. Arthritis Rheum 2012;64 Suppl 10:301.
  59. G Mamyrova, LG Rider, O Jones, A Ehrlich, LM Pachman, R Nickeson, LG Criscione-Schreiber, FW Miller, LK Jung and JD Katz. Environmental Factors Associated With Disease Flare In Juvenile and Adult Dermatomyositis. Arthritis and Rheumatism 2013. 65 (suppl).  S888.
  60. Pachman LM, Morgan GA,Huskin A, Malaisrie SC, Spevak L, Doty S, Boskey A. Structure of calcifications In Juvenile Dermatomyositis differs from calcified aortic valves removed from adults without JDM. Arthritis Rheum 2013;93 Suppl 10:228.
  61. Pachman LM, McMahon MA, Polonsky T, Morgan GA, Amoruso M, Huang C. A pilot study of young adults with Juvenile Dermatomyositis with decreased nailfold capillary end row loops: brachial artery reactivity and oxidized lipids. Arthritis Rheum. 2013;539(10):1277.
  62. Morgan, GA et al Dermatomyositis. Utility and reliability of digital nailfold capillaroscopy in children with Juvenile Dermatomyositis: three methods. Arthritis and Rheum. 2013;888(10):2083.
  63. Xu D, Kachaochana A, Morgan GA, Huang C, Pachman LM. Downregulation of mir-10a is associated with increased von willebrand factor antigen, disease activity score and earlier diagnosis in children with untreated Juvenile Dermatomyositis. Arthritic and Rheum 2013: 890 Suppl 10:2089.
  64. Habers GE, Huber AM, Mamyrova G, O'Hanlon TP, Adams S, Pandey JP, Miller FW, Boonacker C, van Royen-Kerkhof A, Rider LG.  A25: the association of immunogenetic and environmental factors with disease course in patients with juvenile idiopathic inflammatory myopathies.  Arthritis Rheumatol. 2014 Mar;66 Suppl 11:S39-40. doi: 10.1002/art.38441.
  65. Rider LG, Aggarwal R, Bayat N, Erman B, Feldman BM, Huber AM, Cimaz R, Cuttica RJ, de Oliveira SF, Lindsley CB, Pilkington CA, Punaro MG, Ravelli A, Reed AM, Rouster-Stevens KA, van Royen-Kerkhof A, Villa L, Rinaldi M, Pistorio A, Rockette H, Lachenbruch PA, Miller FW, Vencovsky J and Ruperto N.  A Hybrid Conjoint Analysis Model Is Proposed As the Definition of Minimal, Moderate and Major Clinical Improvement in Juvenile Dermatomyositis Clinical Trials.  Arthritis Rheumatol. 2014; 66 (S11): S578.
  66. Habers GEA, Huber AM, Mamyrova G, Targoff I, Boonacker C, van Brussel M, Miller FW, Rider LG, van Royen-Kerkhof.  Anti-p155/140 Autoantibodies and Selected Features at Illness Onset Are Associated with a Chronic Course of Illness in the Juvenile Idiopathic Inflammatory Myopathies. Arthritis Rheumatol. 2014; 66 (S11): S579.
  67. Mamyrova G, Wu L, Huber A, Targoff IN, Miller FW, Rider LG.  Illness Onset Features and Misdiagnosis in Juvenile Idiopathic Inflammatory Myopathies (JIIM) Differ Among Clinical and Autoantibody (Ab) Subgroups. Arthritis Rheumatol. 2014; 66 (S11): S579.
  68. Bussey MR, Morgan GA, Amoruso MC, Rahmani B, Ryan ME, Pachman LM. Decreased CD3- CD16CD56+ natural killer cell counts are associated with disease activity in children with Orbital Myositis. Arthritis Rheum. 2014;66(10):S583.
  69. Pachman LM, Kachaochana A, Morgan GA, Xu D, Huang CC, Chauhan AK. Increased immune complex levels in children with Juvenile Dermatomyositis are not associated with levels of von willebrand factor antigen, C4, duration of illness, disease activity score, or the absolute NK count. Arthritis Rheum. 2014;66(10):S968.
  70. Xu D, Kachaochana A, Ostrower A, Coon JS, Morgan GA, Zhao H, Huang CC, Bulun SE, Pachman LM. Aromatase gene expression is upregulated in diagnostic muscle biopsies from girls with untreated Juvenile Dermatomyositis. FOCIS 2015, presented as a poster.

PRINT THIS ARTICLE